RESEARCH



Association between higher triglyceride glucose index and increased risk of osteoarthritis: data from NHANES 2015– 2020



Jie Huang^{1,2}, Rigbat Rozi¹, Jingbo Ma¹, Bensheng Fu¹, Zhengcao Lu^{1,3}, Jiang Liu¹ and Yu Ding^{1,2,3*}

Abstract

Background The relationship between the triglyceride glucose (TyG) index and osteoarthritis (OA) remains unclear. The objective of this study was to examine potential associations between an elevated TyG index and an increased risk of OA prevalence.

Methods 3,921 participants with OA from the National Health and Nutrition Examination Survey (2015–2020) were included in this study. Participants were categorized into quartiles based on TyG index, which was determined using the formula: Ln [triglyceride (mg/dL) fasting blood glucose (mg/dL)/2]. Weighted multivariable regression, subgroup analyses, and threshold effect analyses were performed to calculate the independent association between TyG index and OA.

Results A total of 25,514 people were enrolled, with a mean TyG index of 8.48 ± 0.65 . The results of multivariable logistic regression analysis after full adjustment showed a significant association between higher TyG index values and an increased risk of OA. Specifically, each incremental unit increase in the TyG index was associated with a 634% higher risk of OA [OR = 7.34; 95% CI: 2.25, 23.93; p = 0.0010]. Based on interaction tests, age, gender, BMI, and smoking status did not significantly affect the relationship between the TyG index and OA, while diabetes showed a stronger positive correlation between the TyG index and OA.

Conclusion An increased risk of OA was associated with a higher TyG index. TyG could be a valuable predictor of OA and offer novel perspectives on the assessment and treatment of OA.

Keywords Triglyceride-glucose index, Osteoarthritis, Insulin resistance, National health and nutrition examination survey

*Correspondence: Yu Ding cosmos_dingyu@163.com ¹Orthopedics of TCM Senior Department, The Sixth Medical Center of PLA General Hospital, 100048 Beijing, China ²Department of Orthopaedics, School of Medicine, South China University of Technology, 510006 Guangzhou, China;, China ³Department of Orthopaedics, School of Medicine, Jinzhou Medical University, 121001 Jinzhou, China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Osteoarthritis (OA) is a prevalent cause of impairment and a substantial factor in the financial burden experienced by older individuals [1-3]. The prevalence of this illness has experienced a significant increase in recent decades, primarily due to the demographic shift towards an aging population and the escalating rate of obesity [4]. The economic impact of OA in several affluent countries has been estimated to account for approximately 1-2.5%of their gross domestic product [5]. Compared with 2020, there is an anticipated substantial increase in the prevalence of OA projected for the year 2050. The projected increase in prevalence rates for different types of OA are as follows: knee OA (KOA) is estimated to increase by 74.9% (with a range of 59.4-89.9), hand OA by 48.6% (with a range of 35.9-67.1), hip OA by 78.6% (with a range of 57.7-105.3), and other forms of OA by 95.1% (with a range of 68.1–135.0) [6]. Hence, it is vital to expeditiously recognize and intervene in instances of OA in order to mitigate its prevalence.

Insulin resistance (IR) is a prevalent feature observed in persons diagnosed with type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, and cardiovascular disease. It denotes a reduced responsiveness to the physiological impacts of insulin. Numerous observational studies have provided strong evidence indicating a noteworthy correlation between diabetes and OA, with the latter ascribed to insulin resistance [7]. The TyG index is derived through a mathematical computation involving the fasting triglyceride and glucose values' logarithm. The indicator of IR, which is a precursor to T2DM, has been universally acknowledged as a distinct and reliable measure [8]. The evidence suggests a correlation between the TyG index and the prognosis of several illnesses, such as



Fig. 1 Sample selection flowchart from NHANES 2015–2020

cardiovascular disease, kidney stones, erectile dysfunction, and dementia [9-13].

Accumulating evidence suggests that IR may increase the risk of developing OA. In a study conducted by Martine Duclos et al. [14], it was observed that elevated blood glucose levels could lead to inflammation and cartilage degeneration through oxidative stress, accumulation of inflammatory mediators, and advanced glycation end-products. Florent Eymard et al. [15] suggested that T2DM prediction decreased joint space in men with established KOA. Additionally, it was noted by Daisuke Hamada et al. [16] T2DM could increase vulnerability to the beginning and development of OA by encouraging IR expression. Moreover, Zaharia et al. [17] demonstrated that IR is connected to both musculoskeletal function and symptoms of arthritis in both T2MD patients and metabolically healthy people. In addition, Bradley et al. [18] showed that leptin and the interleukin-1 receptor antagonist were connected to IR and OA strengthened the case for a link between T2DM and OA. Thus, there may be a connection between the TyG index and OA because it has been suggested that the TyG index is an IR marker. However, the correlation between TyG index and OA has never been examined in a prior study.

It is conceivable to speculate about a potential correlation between the TyG index and the occurrence of OA, given the claim that the TyG index serves as an indicator of IR. However, more investigation is required into the relationship between the TyG index and the prevalence of OA. Therefore, this study aims to examine the relationship between the TyG index and OA in a sizable, nationally representative cohort of Americans. The National Health and Nutrition Examination Survey (NHANES) from 2015 to 2020 provided the data for this investigation.

Methods

Study design and population

The NAHNES is a research initiative conducted by the National Centre for Health Statistics (NCHS) aimed at gathering comprehensive health and nutrition data pertaining to the population of the United States. In order to achieve a representative sample of study participants, the organization employed a sampling methodology that incorporated stratification, multiple stages, and clustering based on probability. Additionally, prior to initiating the project, all participants had provided written informed consent for the collection of data. The information from the NHANES from 2015 to 2020 was reviewed in the current study. This analysis found that a significant fraction of the 25,514 people who were declared appropriate lacked TyG data for 20,864 people and OA data for 729 people. As seen in Fig. 1, the study ultimately enrolled 3,921 participants.

Definitions of TyG and OA

The formula determines the TyG index: Ln [Fasting triglycerides (mg/dL) × Fasting glucose (mg/dL)/2]=TyG [19]. Data from self-reported personal interviews include information on arthritis diagnosis. Participants were asked if they had ever been informed that they had arthritis by a doctor or other medical expert. If "yes," they were asked to categorize their arthritis diagnosis as OA, rheumatoid arthritis, psoriatic arthritis, and others. Prior research has substantiated the veracity of self-reported OA problems [20].

Covariables

The factors that might muddle the TyG index and OA connection were summarised using the multivariableadjusted models. Our study's covariates included a range of demographic and health-related variables, including age (measured in years), gender (categorized as male or female), race, education level, poverty-to-income ratio (PIR), smoke status (Smoked at least 100 cigarettes in life), alcohol consumption (dichotomized as drinking at least once a month or not), hypertension, diabetes, moderate physical activity, Body Mass Index (BMI), high-Density Lipoprotein Cholesterol (HDL cholesterol), low-Density Lipoprotein Cholesterol (LDL cholesterol), insulin, homeostatic model assessment of insulin resistance (HOMA-IR), alanine transaminase (ALT), aspartate aminotransferase (AST), C-Reactive Protein (CRP), blood urea nitrogen (BUN), and uric acid (UA). The BMI was divided into three ranges: $25 \le$, 25-30, and \geq 30 g/cm², which correspond to persons who are average weight, overweight, and obese, respectively. The public can access the detailed measurement techniques for the research variables at www.cdc.gov/nchs/nhanes/, the official website of the Centres for Disease Control and Prevention (CDC).

Statistical analysis

The categorization of continuous variables was determined by considering their distribution properties. The researchers computed weighted means and their corresponding standard errors for constant data. Weighted frequency percentages were also computed for categorical variables. The TyG index's quartile groupings were compared using either the Chi-squared or Kruskal-Wallis H test. The research used multivariate logistic regression models to examine the relationship between the TyG index and OA. In this study, three distinct models were employed. There were no modifications made to Model 1. Modifications were implemented in Model 2 concerning age, gender, and racial variables. In Model 3, adjustments were made for various demographic and health-related factors, including age, gender, race, education level, PIR, smoke status, alcohol consumption, hypertension, diabetes, moderate physical activity, BMI, HDL cholesterol, LDL cholesterol, insulin, HOMA-IR, ALT, AST, CRP, BUN, and UA. This study employed a weighted generalized additive model (GAM) regression using a penalized spline technique to evaluate the nonlinear relationship between the TyG index and OA. To better evaluate the nonlinear relationship between the TyG index and OA, threshold effect analysis was conducted. Moreover, a stratified multivariate regression analysis was conducted to perform subgroup analysis according to age, gender, BMI, smoking status, and diabetes. Furthermore, the incorporation of an interaction term facilitated the assessment of potential differences in relationships across subgroups. A p-value equal to or less than 0.05 was deemed statistically significant. The analyses were conducted using R version 3.4.3 (The R Foundation, http://www.R-project.org) and Empower software (X&Y Solutions, Inc., Boston, MA, USA).

Results

Baseline characteristics of participants

Table 1 presents the weighted demographic baseline characteristics of the people involved in the study. The study comprised a sample size of 25,514 individuals, with 49.06% male and 50.94% female. The participants had an average age of 48.05 ± 17.23 years. The average value of the TyG index was found to be 8.48 ± 0.65 . The TyG index values for quartiles 1 to 4 were ≤ 8.02 , 8.02-8.47, 8.48-8.93, and ≥ 8.93 . The total average prevalence of OA was found to be 14.37%. When examining the data by quartiles, the prevalence rates were 9.05% for Quartile 1, 12.76% for Quartile 2, 18.25% for Quartile 3, and 17.66% for Quartile 4.

Higher TyG index is associated with a greater risk of OA

An affirmative correlation between the TyG index and OA was observed. In the third model, after adjusting for all relevant factors, the positive link remained consistent [OR=7.34; 95% CI: 2.25, 23.93; *p*=0.0010]. This suggests that for every unit rise in the TyG index, there is a 634% higher risk of developing OA. In addition, we discretized the TyG index, originally a continuous variable, into quartiles to do a sensitivity analysis. A statistically significant 69% higher probability of OA was reported in Quartile 4 compared to Quartile 1, representing the lowest TyG index quartile. Furthermore, the observed p trend suggests that the upward trend observed in all models is statistically significant, implying a propensity for the risk of OA to increase as the TyG index increases. The provided information is presented in Table 2. In order to investigate the nonlinear association between the TyG index and OA, weighted GAM and smooth curve fits were utilized. Our study's findings revealed no discernible nonlinear association between the TyG index and OA, as

Table 1 Baseline characteristics of participants, weighted

Q1Q2Q3Q4 $Age [ward]$ 40.67 ± 16.67 48.49 ± 17.62 51.09 ± 16.41 52.24 ± 15.72 <0.0001 $Age [ward]$ 41.18 47.65 51.87 55.91 <0.0001 $Male$ 41.18 47.65 51.87 55.91 <0.0001 $Brande$ 58.82 52.25 48.13 44.09 $BR (%)$ 319 ± 15.4 3.08 ± 1.56 3.05 ± 1.60 297 ± 1.51 <0.0163 $Bare (%)$ 7.77 8.42 6.98 $Other Hispanic5.337.778.426.98Other Hispanic white61.7462.0862.1364.69Other Hispanic White12.7411.988.7550.41Other Hispanic White12.7419.0519.9319.38Other Hispanic White12.7719.0519.3319.3319.38Other All (%)VVVVVOther Hispanic Mile14.9719.0319.3319.340.0070Mile School22.6625.6027.7325.34Abore high School0.26855.7757.3155.28C.00001Other Hispanic Mile14.979.9346.6657.22C.0001Other Hispanic Mile58.0560.2055.7749.9444.22No.66Other Hispanic Mile11.9539.8042.335$	Variables	Quartiles of TyG				P value
Age (sear) 40.67±16.67 48.49±17.62 51.09±16.41 52.24±15.72 <0.0001		Q1	Q2	Q3	Q4	
Čander (%) </td <td>Age [year]</td> <td>40.67±16.67</td> <td>48.49±17.62</td> <td>51.09 ± 16.41</td> <td>52.24±15.72</td> <td>< 0.0001</td>	Age [year]	40.67±16.67	48.49±17.62	51.09 ± 16.41	52.24±15.72	< 0.0001
Male41.1847.6551.8755.91Female58.8252.3546.1344.09Female58.8252.3580.512.375.150.0163Roce fig5.307.778.426.98Non-Hispani kuhte5.537.778.426.985.04Non-Hispani kuhte61.746.088.455.045.04Other races8.2310.6110.9711.661.070Under high school14.9719.0319.0019.301.03High school equivalent2.365.572.7315.513.04Nor-Hispani kuhte6.2685.572.7315.583.04Overweight (2.58 kg/m²)0.546.82.73.5513.184-Nord Bild School19.913.59346.6657.22Overweight (2.58 kg/m²)19.913.5934.66657.22<	Gender (%)					< 0.0001
female58.8252.3548.1344.09 <i>RP</i> (M)3.19.1.543.08 ± 1.503.05 ± 1.609.72 ± 1.510.0163 <i>RP</i> (M)3.19.1.543.08 ± 1.503.05 ± 1.609.72 ± 1.510.0163 <i>RP</i> (M)7097.5610.0311.63Other Hispanic5.537.778.426.96Non-Hispanic shifte10.1410.866.136.46Non-Hispanic black17.4111.988.055.04Other aces8.2310.6110.9711.66High school requivalent2.542.542.735.28High school requivalent2.665.577.315.28 <i>Normal</i> [MM-25 kg/m²)0.542.827.831.84Overweight (25 sGM1'30 kg/m²)2.9553.7253.5153.184Orese (M) 20 kg/m²)2.9553.7253.5573.184Obes (M) 20 kg/m²)2.9553.7244.42350.06Normal [M-25 kg/m²)1.9153.8403.8403.8403.840Obes (M) 20 kg/m²)2.9553.3744.9474.4224.0001Normal (M-25 kg/m²)1.5505.3743.8493.9513.744.974.9234.0001No (Smoked < 100 cigarettes in life)5.803.3744.9474.9234.00014.0001No (Smoked < 100 cigarettes in life)5.803.3748.9494.9325.935.754	Male	41.18	47.65	51.87	55.91	
Phi (%)3.19±1543.08±1.563.05±1.602.97±1.510.0163 (0.0001)Race (%)7.977.5610.0311.63(0.0001)Weskan American5.537.778.426.46(0.001)Non-Hispanic white61.7462.086.21364.69(0.001)Non-Hispanic black17.141.988.455.04(0.001)Other races8.2310.0710.0711.66(0.001)Elicariton key (%)1.49719.0319.9019.38(0.001)High school or equivalent2.2565.575.2135.22(0.001)Above high school1.49719.0319.9019.38(0.001)Norma (KM)2.2565.575.311.84(0.001)Overweight (25.64M)'30 kg/m²)19.913.59340.665.722(0.001)Obese (M)5.573.5513.84(0.001)(0.001)(0.001)Cigarette bee (%)41.053.93044.2350.66(0.001)Ves (Sinoked < 100 cigarettes in life)	Female	58.82	52.35	48.13	44.09	
Race (%) </td <td>PIR (%)</td> <td>3.19±1.54</td> <td>3.08 ± 1.56</td> <td>3.05 ± 1.60</td> <td>2.97±1.51</td> <td>0.0163</td>	PIR (%)	3.19±1.54	3.08 ± 1.56	3.05 ± 1.60	2.97±1.51	0.0163
Mexican American7.097.5610.0311.6311.93Other Hispanic white5.337.778.426.98Non-Hispanic black17.4111.988.455.04Non-Hispanic black17.4111.988.455.04Other aces8.2310.0110.9719.38Education level (%)19.9319.9019.38Under high school or equivalent2.2625.4027.315.28Mt (%)5.575.577.3119.40Overweight (25.54 km²n)50.5426.8217.8319.44Overweight (25.54 km²n)19.913.59346.663.22Overweight (25.54 km²n)19.913.59346.667.22Cigarette Level (%)19.913.59344.2350.06Vers (Smoked 2100 cigarettes in life)5.8056.205.77749.44Ves (Smoked 2100 cigarettes in life)5.8073.7474.9474.22No (dink no more than once a month)5.5033.7444.9474.050Ves (dink at least once a month)5.8022.7178.4994.05No2.4347.2178.4997.924.0001No (dink no more than once a month)5.122.122.065.00No9.939.112.94.0001.0001No9.939.122.94.0001.0001No9.939.122.94.0001.0001No9.939.141.634 <td>Race (%)</td> <td></td> <td></td> <td></td> <td></td> <td>< 0.0001</td>	Race (%)					< 0.0001
Other Hispanic553777842698988Non-Hispanic white61.7462.0861.6961.69Non-Hispanic black11.7411.9884.055.04Other races82.310.6110.9711.66Education level (%)1.90711.66	Mexican American	7.09	7.56	10.03	11.63	
Non-Hispanic black61.7462.0862.1364.69Non-Hispanic black17.4111.988.455.04Other races8.2310.6110.9711.66Education level (%)9.0319.9019.38Under high school6.2685.5757.3155.28Above high school6.2685.55757.3110.94Normal (BML 25 kg/m²)29.5426.8217.8310.94Overweight (25 s BMI '30 kg/m²)29.5537.2535.5131.84Obese (BML 23 kg/m²)29.5537.2535.5131.84Cigarette Jac (%)4.2350.0610.02Ves (famk at least once a month)5.8060.2055.7749.94No (Smoked < 100 cigarettes in life)	Other Hispanic	5.53	7.77	8.42	6.98	
Nan-Hispanic black17.4111.988.455.04Other races8.2310.5110.9711.66Education level (%)19.3319.9019.3819.90Under high school22.365.4027.7925.34Above high school62.6855.7057.3155.2810.94M(%)50.5462.6817.8310.9410.94Overweight (25 skg/m²)50.5437.2535.5131.84Overweight (25 skg/m²)9.9537.2535.5131.84Obese (6M.23 okg/m²)19.9135.9344.6657.22Cigarette Use (%)58.9560.2057.7749.94Koffsched = 100 cigarettes in life)58.9560.2057.7749.94Atcohol Use (mk)55.8063.259.9450.007.0001Yes (strick at least once a month)55.8053.7449.4744.224.0001No (drink no more hanonce a month)55.8053.7449.4745.931.0001Yes17.5727.1738.4945.931.00011.0001No27.6552.1112.0927.064.0001No27.847.978.42.992.12.43.0464.0001No27.857.127.07.98.0067.851.0002No27.857.127.02.9231.002.12.43.0464.0001No27.8413.01.10.3516.34.29.902.12.43.0464.0001No19.31.17<	Non-Hispanic white	61.74	62.08	62.13	64.69	
Other races8.2310.6110.9711.66Education level (%)1.9719.0319.009.38High school or equivalent22.3625.4022.7925.34Above high school62.6855.7557.3152.80MI (%)0.55426.8217.8310.94Overavelght (25.5 \$M/ 30 kg/m?)29.5537.5535.5131.84Obese (8M1≥30 kg/m?)19.9135.9346.6552.20Cigarette Use (%)4.2350.06Veravelght (25.5 \$M/ 30 kg/m?)19.9139.8041.2350.06Cigarette Use (%)4.2350.06Veravelght (25.6 \$M/ 30 kg/m?)55.8035.744.9474.122Yes (Smoked > 100 cigarettes in life)41.0539.8041.3350.06No (Smoked > 100 cigarettes in life)55.8035.744.9474.122Yes (drink at least once a month)55.8035.744.9474.122No (drink no more than once a month)55.8035.749.974.07Yes17.5727.1738.494.593No20.7552.1112.097.06<0.0001	Non-Hispanic black	17.41	11.98	8.45	5.04	
Éducation level (%)	Other races	8.23	10.61	10.97	11.66	
Under high school14.9719.0319.9019.38High school or equivalent22.3625.4027.9025.34Above high school or equivalent62.6855.5757.3155.28M(%)55.5757.3110.94Normal (BMI < 25 kg/m²)	Education level (%)					0.0070
High school or equivalent22.3625.4022.7925.3425.73Above high school62.6855.5757.3155.28AbM (%)50.5426.8217.8310.94Normal (BML<25 kg/m²)	Under high school	14.97	19.03	19.90	19.38	
Above high school62.6855.5757.3155.28BMI (%)<	High school or equivalent	22.36	25.40	22.79	25.34	
BMI (%) · · <t< td=""><td>Above high school</td><td>62.68</td><td>55.57</td><td>57.31</td><td>55.28</td><td></td></t<>	Above high school	62.68	55.57	57.31	55.28	
Normal (BMI < 25 kg/m²) 50.54 26.82 17.83 10.94 Overweight (25 kBMI '30 kg/m²) 19.91 35.93 46.66 57.22 Cobese (BMI ≥ 30 kg/m²) 19.91 35.93 46.66 57.22 Cigarette Use (%) ************************************	BMI (%)					< 0.0001
Overweight (25 ≤ BM + 30 kg/m²) 29,55 37,25 35,51 31.84 Obese (BM ≥ 30 kg/m²) 19,91 35,93 46.66 57.22 Cigarette Use (%) Yes (Smoked ≥ 100 cigarettes in life) 58.95 60.20 55.77 49.94 Alcohol Use (%) Yes (drink at least once a month) 55.80 53.74 49.47 44.22 No (drink no more than once a month) 36.10 35.55 39.90 44.05 Yes (drink no more than once a month) 36.10 35.55 38.49 45.93 No 82.43 72.83 61.51 54.07 Ver 97.93 94.79 87.91 72.94 No 32.88 29.21 31.00 32.15 Insulf (LU/L) 193 ± 1.72 2.96 ± 3.25 4.63 ± 2.970 2.04 ± 1.5.6 <.0.001	Normal (BMI < 25 kg/m ²)	50.54	26.82	17.83	10.94	
Obse (B/II ≥ 30 kg/m²) 19.91 35.93 46.66 57.22 Cigarette Use (%) <	Overweight (25 ≤ BMI ^{<} 30 kg/m ²)	29.55	37.25	35.51	31.84	
Cigaretic Use (W) < 41.05 39.80 44.23 50.06 Yes (Smoked < 100 cigarettes in life)	Obese (BMI \ge 30 kg/m ²)	19.91	35.93	46.66	57.22	
Yes (spinoked ≥ 100 cigarettes in life)41.0539.8044.2350.06No (Smoked < 100 cigarettes in life)58.9560.2055.7749.94Alcohol Use (%)55.8053.7449.4744.22Yes (drink at least once a month)36.1035.5539.9044.05No (drink no more than once a month)36.1035.5539.9044.05Mo (drink no more than once a month)36.1025.5538.4945.93No82.4372.8361.5154.07Diabetes (%)72.8361.5154.07No20.75.2112.0927.06<0.0001	Cigarette Use (%)					< 0.0001
No (Smoked < 100 cigarettes in life) 58.95 60.20 55.77 49.94 Alcohol Use (%)	Yes (Smoked ≥ 100 cigarettes in life)	41.05	39.80	44.23	50.06	
Alcohal Use (%) 55.80 53.74 49.47 44.22 Yes (drink at least once a month) 36.10 35.55 39.90 44.05 Hypertension (%) Yes 17.57 27.17 38.49 45.93 No 82.43 72.83 61.51 54.07 Diabetes (%) Yes 2.07 5.21 12.09 27.06 <0.001	No (Smoked < 100 cigarettes in life)	58.95	60.20	55.77	49.94	
Yes (drink at least once a month)55.8053.7449.4744.22No (drink no more than once a month)36.1035.5539.9044.05Hypertension (%)<	Alcohol Use (%)					< 0.0001
No (drink no more than once a month) 36.10 35.55 39.90 44.05 Hypertension (%) <	Yes (drink at least once a month)	55.80	53.74	49.47	44.22	
Hypertension (%)	No (drink no more than once a month)	36.10	35.55	39.90	44.05	
No17.5727.1738.4945.93No82.4372.8361.5154.07Diabetes (%)72.8361.5154.07Yes2.075.2112.0927.06<0.0001	Hypertension (%)					< 0.0001
No 82.43 72.83 61.51 54.07 Diabetes (%) 20.7 5.21 12.09 27.06 <0.0001	Yes	17.57	27.17	38.49	45.93	
Diabetes (%) Seam Seam	No	82.43	72.83	61.51	54.07	
Yes2075.2112.0927.06<0.0001No97.9394.7987.9172.94Moderate physical activity (%)76.1270.7969.0067.85Yes76.1270.7969.0032.15Insulin (/µ//L)7.86±6.3411.30±10.3516.34±29.9021.24±30.46<0.0001	Diabetes (%)					
No 97.93 94.79 87.91 72.94 Moderate physical activity (%) 56.22 60.02 67.85 Yes 66.12 70.79 69.00 67.85 No 23.88 29.21 31.00 32.15 Insulin (µU/L) 7.86 ± 6.34 11.30 ± 10.35 16.34 ± 29.90 21.24 ± 30.46 <0.0001	Yes	2.07	5.21	12.09	27.06	< 0.0001
Moderate physical activity (%) 0.0002 Yes 76.12 70.79 69.00 67.85 No 23.88 29.21 31.00 32.15 Insulin (µU/L) 7.86 ± 6.34 11.30 ± 10.35 16.34 ± 29.90 21.24 ± 30.46 <0.0001	No	97.93	94.79	87.91	72.94	
Yes 76.12 70.79 69.00 67.85 No 23.88 29.21 31.00 32.15 Insulin ((µU/L) 7.86 ± 6.34 11.30 ± 10.35 16.34 ± 29.90 21.24 ± 30.46 <0.0001 HOMA-IR 1.93 ± 1.72 2.96 ± 3.25 4.63 ± 8.69 7.49 ± 15.84 <0.0001 $CRP [mg/L]$ 2.45 ± 5.24 4.08 ± 8.02 4.34 ± 6.97 4.64 ± 7.51 <0.0001 $ALT [U/L]$ 18.31 ± 14.12 20.53 ± 14.25 24.38 ± 18.68 26.50 ± 18.00 <0.0001 $AST [U/L]$ 20.71 ± 12.23 21.34 ± 10.68 22.49 ± 14.66 22.26 ± 10.70 0.0037 $BUN [[mg/dL]$ 13.92 ± 4.94 14.41 ± 5.04 14.81 ± 5.45 15.82 ± 6.29 <0.0001 HD_1 -cholesterol [mg/dL] 63.01 ± 16.54 58.05 ± 15.83 50.5 ± 1.42 5.90 ± 1.45 <0.0001 LDL -cholesterol [mg/dL] 95.53 ± 28.11 10.995 ± 32.16 116.46 ± 35.39 117.05 ± 39.72 <0.0001 $TyG [g/cm^2]$ 7.70 ± 0.26 8.25 ± 0.13 8.68 ± 0.13 9.34 ± 0.36 <0.0001 $Osteoarthritis (%)$ 9.05 12.76 18.25 17.66 <0.0001	Moderate physical activity (%)					0.0002
No23.8829.2131.0032.15Insulin ((µU/L)7.86±6.3411.30±10.3516.34±29.9021.24±30.46<0.0001	Yes	76.12	70.79	69.00	67.85	
Insulin ((µU/L) 7.86 ± 6.34 11.30 ± 10.35 16.34 ± 29.90 21.24 ± 30.46 <0.0001 $HOMA-IR$ 1.93 ± 1.72 2.96 ± 3.25 4.63 ± 8.69 7.49 ± 15.84 <0.0001 $CRP [mg/L]$ 2.45 ± 5.24 4.08 ± 8.02 4.34 ± 6.97 4.64 ± 7.51 <0.0001 $ALT [U/L]$ 18.31 ± 14.12 20.53 ± 14.25 24.38 ± 18.68 26.50 ± 18.00 <0.0001 $AST [U/L]$ 20.71 ± 12.23 21.34 ± 10.68 22.49 ± 14.66 22.26 ± 10.70 0.0037 $BUN [[mg/dL]$ 13.92 ± 4.94 14.41 ± 5.04 14.81 ± 5.45 15.82 ± 6.29 <0.0001 $HD_L-cholesterol [mg/dL]$ 4.87 ± 1.27 5.28 ± 1.25 5.65 ± 1.42 5.90 ± 1.45 <0.0001 $LDL-cholesterol [mg/dL]$ 63.01 ± 16.54 58.05 ± 15.83 50.54 ± 1.313 44.53 ± 10.54 <0.0001 $LDL-cholesterol [mg/dL]$ 9.53 ± 28.11 10.99 ± 32.16 116.64 ± 35.39 117.05 ± 39.72 <0.0001 $TyG [g/cm^2]$ 7.70 ± 0.26 8.25 ± 0.13 8.68 ± 0.13 9.34 ± 0.36 <0.0001 $Osteoarthritis (%)$ 9.05 12.76 18.25 17.66 <0.0001	No	23.88	29.21	31.00	32.15	
HOMA-IR1.93±1.722.96±3.254.63±8.697.49±15.84<0.0001CRP [mg/L]2.45±5.244.08±8.024.34±6.974.64±7.51<0.0001	Insulin ((µU/L)	7.86±6.34	11.30 ± 10.35	16.34 ± 29.90	21.24 ± 30.46	< 0.0001
CRP [mg/L] 2.45 ± 5.24 4.08 ± 8.02 4.34 ± 6.97 4.64 ± 7.51 <0.0001	HOMA-IR	1.93 ± 1.72	2.96 ± 3.25	4.63±8.69	7.49±15.84	< 0.0001
ALT [U/L] 18.31 ± 14.12 20.53 ± 14.25 24.38 ± 18.68 26.50 ± 18.00 <0.0001AST [U/L] 20.71 ± 12.23 21.34 ± 10.68 22.49 ± 14.66 22.26 ± 10.70 0.0037 BUN [[mg/dL] 13.92 ± 4.94 14.41 ± 5.04 14.81 ± 5.45 15.82 ± 6.29 <0.0001	CRP [mg/L]	2.45 ± 5.24	4.08±8.02	4.34±6.97	4.64±7.51	< 0.0001
AST [U/L] 20.71 ± 12.23 21.34 ± 10.68 22.49 ± 14.66 22.26 ± 10.70 0.0037 BUN [[mg/dL] 13.92 ± 4.94 14.41 ± 5.04 14.81 ± 5.45 15.82 ± 6.29 <0.0001	ALT [U/L]	18.31±14.12	20.53 ± 14.25	24.38±18.68	26.50 ± 18.00	< 0.0001
BUN [[mg/dL] 13.92 ± 4.94 14.41 ± 5.04 14.81 ± 5.45 15.82 ± 6.29 <0.0001UA [mg/dL] 4.87 ± 1.27 5.28 ± 1.25 5.65 ± 1.42 5.90 ± 1.45 <0.0001	AST [U/L]	20.71±12.23	21.34±10.68	22.49 ± 14.66	22.26 ± 10.70	0.0037
$UA [mg/dL]$ 4.87 ± 1.27 5.28 ± 1.25 5.65 ± 1.42 5.90 ± 1.45 <0.0001 $HDL-cholesterol [mg/dL]$ 63.01 ± 16.54 58.05 ± 15.83 50.54 ± 13.13 44.53 ± 10.54 <0.0001 $LDL-cholesterol [mg/dL]$ 95.53 ± 28.11 109.95 ± 32.16 116.46 ± 35.39 117.05 ± 39.72 <0.0001 $TyG [g/cm^2]$ 7.70 ± 0.26 8.25 ± 0.13 8.68 ± 0.13 9.34 ± 0.36 <0.0001 Osteoarthritis (%) 9.05 12.76 18.25 17.66 <0.0001	BUN [[mg/dL]	13.92 ± 4.94	14.41 ± 5.04	14.81 ± 5.45	15.82±6.29	< 0.0001
HDL-cholesterol [mg/dL] 63.01±16.54 58.05±15.83 50.54±13.13 44.53±10.54 <0.0001 LDL-cholesterol [mg/dL] 95.53±28.11 109.95±32.16 116.46±35.39 117.05±39.72 <0.0001	UA [mg/dL]	4.87±1.27	5.28 ± 1.25	5.65 ± 1.42	5.90 ± 1.45	< 0.0001
LDL-cholesterol [mg/dL] 95.53±28.11 109.95±32.16 116.46±35.39 117.05±39.72 <0.0001 TyG [g/cm²] 7.70±0.26 8.25±0.13 8.68±0.13 9.34±0.36 <0.0001	HDL-cholesterol [mg/dL]	63.01 ± 16.54	58.05 ± 15.83	50.54 ± 13.13	44.53±10.54	< 0.0001
TyG [g/cm²]7.70±0.268.25±0.138.68±0.139.34±0.36<0.0001Osteoarthritis (%)9.0512.7618.2517.66<0.0001	LDL-cholesterol [mg/dL]	95.53±28.11	109.95 ± 32.16	116.46±35.39	117.05±39.72	< 0.0001
Osteoarthritis (%) 9.05 12.76 18.25 17.66 < 0.0001	TyG [g/cm²]	7.70±0.26	8.25±0.13	8.68±0.13	9.34±0.36	< 0.0001
	Osteoarthritis (%)	9.05	12.76	18.25	17.66	< 0.0001

Mean ± SD for continuous variables: the P value was calculated by the weighted linear regression model. (%) for categorical variables: the P value was calculated by the weighted chi-square test

PIR, Poverty-to-income ratio; BMI, body mass index; HOMA-IR: homeostatic model assessment of insulin resistance; CRP, C-Reactive Protein; ALT, alanine transaminase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; UA, uric acid; HDL-cholesterol, high-Density Lipoprotein Cholesterol; LDL-cholesterol, low-Density Lipoprotein Cholesterol; TyG, Triglyceride–Glucose

Table 2 Association between TyG and OA

	OR (95% CI), <i>p</i> value		
	Model 1	Model 2	Model 3
Osteoarthritis			
TyG index	9.52 (4.13,	8.54 (3.41,	7.34 (2.25,
	21.92)<0.0001	21.37) < 0.0001	23.93) 0.0010
Categories			
Quartile 1	Reference	Reference	Reference
Quartile 2	1.26 (0.94, 1.68) 0.1217	1.15 (0.85, 1.56) 0.3523	1.12 (0.82, 1.54) 0.4760
Quartile 3	1.76 (1.34, 2.32) < 0.0001	1.60 (1.20, 2.14) 0.0015	1.62 (1.17, 2.25) 0.0036
Quartile 4	1.93 (1.47, 2.54) < 0.0001	1.76 (1.31, 2.35) 0.0002	1.69 (1.18, 2.42) 0.0039
P for trend	9.52 (4.13, 21.92)<0.0001	1.49 (1.24, 1.79) < 0.0001	1.45 (1.16, 1.83) 0.0014

Data are presented as ORs, 95% CIs, and P-value

Model 1: adjusted for nothing

Model 2: adjusted for age, gender, and race

Model 3: adjusted for age, gender, race, education level, PIR, smoke status, alcohol consumption, hypertension, diabetes, moderate physical activity, BMI, HDL cholesterol, LDL cholesterol, insulin, HOMA-IR, ALT, AST, CRP, BUN, and UA

ALT: alanine transaminase; AST: aspartate aminotransferase; BMI: body mass index; BUN: blood urea nitrogen; CI: confidence interval; CRP: C-Reactive Protein; HDL cholesterol: high-Density Lipoprotein Cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance; LDL cholesterol: low-Density Lipoprotein Cholesterol; OR: odds ratio; PIR:Poverty-to-income ratio; TyG: Triglyceride–Glucose; UA; uric acid

depicted in Fig. 2. Moreover, Cox proportional hazards regression models were conducted. Based on threshold effect analysis, we identified the inflection points for OA as 9.67 (*P* values for log-likelihood ratio < 0.05) (Table 3).

Subgroup analysis

A subgroup analysis assessed the strength and reliability of the association between the TyG index and OA. The study examined the potential effects of age, gender, BMI, smoking status, and diabetes on the observed interactions. Nevertheless, our analysis did not find any statistically significant association between age, gender, BMI, and smoking status concerning this association. This suggests that the factors mentioned above do not significantly impact the observed relationship (all p for interaction>0.05). Our study's findings indicate a consistent positive correlation between the TyG index and OA across many groups, regardless of age, gender, BMI, smoking status, and diabetes. Interestingly, the participants without diabetes showed a stronger positive correlation between the TyG index and OA (p for interaction < 0.05). However, it is important to note that the NHANES data did not explicitly distinguish between T1MD and T2MD in its research design. Therefore, we could not run the subgroup analysis stratified by T1MD and T2MD further. This suggests that the relationship

between these variables may be applicable in various demographic contexts, as seen in Table 4.

Discussion

Our results show a statistically significant independent connection between raised TyG index levels and a higher likelihood of OA in this cross-sectional investigation, which included 25,514 participants. The subgroups stratified by age, gender, BMI, smoking status, and diabetes showed similarity in the detected link. Starting IR treatment and management earlier in life may have positive effects on reducing or preventing the occurrence of OA.

This is the first investigation of the relationship between the TyG index and OA. Numerous additional clinicopathological variables have been linked to OA in other research. Chen et al. [20] found a correlation between the frequency of OA and the levels of thyroid hormone sensitivity (central and peripheral). Lower blood 25-(OH)D levels were substantially and non-linearly linked to more significant risks of all-cause and cardiovascular diseases mortality in American people with OA, according to Xiao et al. [21]. Biological age, phenotypic age, and telomere length were revealed to have substantial mediating effects on the association of metals with OA risk by Chen et al. [22]. It has been shown in earlier research that inflammation and the TyG index are highly related. Li et al. [23] demonstrated that higher levels of inflammation and the TyG index, both individually and in combination, increased the risk of colorectal cancer. Moreover, Yan et al. [24] elucidated that among Americans under 60 with average weight and no diabetes, the TyG index was positively linked with arthritis. A combined predictor to represent innate and adaptive immunity in response to cancer, the systemic inflammatory response index (SIRI) was developed initially [25]. SIRI is a newly discovered biomarker for OA disease activity assessment [26]. The NF-KB and NLRP3 signaling pathways collaborate to support P2×7-induced chondrocyte extracellular matrix breakdown and pyroptotic inflammation, according to Li et al. [27]. In addition, Philpott et al. [28] showed how cannabidiol might delay the onset of chronic joint pain by inhibiting early OA-related inflammation. OA is a disease of the whole joint, affecting the synovium, tendons, muscles, ligaments, subchondral bone, adipose tissue, and articular cartilage. It may even be a systemic illness, with inflammation playing a crucial part in the interaction of the joint tissues [29]. Greene et al. [4] suggested that "inflame-aging"-or age-associated inflammationand the onset of OA may be connected. Furthermore, the study conducted by Jin et al. [30] showed that limonin can inhibit NF-KB activation in chondrocytes. This inhibition occurs via the activation of the Nrf2/HO-1 cascade, significantly reducing the inflammatory response and catabolic processes induced by IL-1 β . It has also been



Fig. 2 Association between TyG index and OA by the GAM. The solid red line represents the smooth curve fit between variables. Blue bands represent the 95% confidence bands derived from the fit

Table 3 Thresh	old effect	analysis of T	vG index and O	A
----------------	------------	---------------	----------------	---

Osteoarthritis	OR (95% CI)	<i>p</i> value
TyG index		
Inflection point		9.67
TyG index < Inflection point	1.54 (1.24, 1.91)	0.0001
TyG index > Inflection point	0.28 (0.07, 1.14)	0.0746
Log-likelihood ratio		0.015
Data are presented as OR, 95% CI,	and <i>p</i> value	

Model 1: adjusted for nothing

Model 2: adjusted for age, gender, and race

Model 3: adjusted for age, gender, race, education level, PIR, smoke status, alcohol consumption, hypertension, diabetes, moderate physical activity, BMI, HDL cholesterol, LDL cholesterol, insulin, HOMA-IR, ALT, AST, CRP, BUN, and UA

ALT: alanine transaminase; AST: aspartate aminotransferase; BMI: body mass index; BUN: blood urea nitrogen; CI: confidence interval; CRP: C-Reactive Protein; HDL cholesterol: high-Density Lipoprotein Cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance; LDL cholesterol: low-Density Lipoprotein Cholesterol; OR: odds ratio; PIR:Poverty-to-income ratio; TyG: Triglyceride–Glucose; UA; uric acid

claimed that inflammation is favorably related to IR, and in TNF-treated Gulo-/- mice, Qing et al. [31] revealed that vitamin C deficiency worsens IR, which may partly be due to the loss of the anti-inflammation effect. Protein tyrosine phosphatase 1B (PTP1B) is a regulatory enzyme that catalyzes the removal of phosphate groups from phosphoserine residues found in insulin receptor
 Table 4
 Subgroup analysis

	Osteoarthritis	
	OR (95% CI), <i>p</i> value	P for in-
		teraction
Stratified by gender		0.4823
Male	1.28 (0.95, 1.71) 0.0989	
Female	1.46 (1.13, 1.88) 0.0036	
Stratified by age		0.2983
Age < 65	1.47 (1.16, 1.87) 0.0015	
Age≥65	1.21 (0.89, 1.65) 0.2287	
Stratified by BMI		0.0923
Normal (BMI < 25 kg/m ²)	2.12 (1.28, 3.52) 0.0037	
Overweight (25≤BMI [≤] 30 kg/m²)	1.38 (0.99, 1.92) 0.0574	
Obese (BMI≥30 kg/m²)	1.24 (0.94, 1.64) 0.1330	
Stratified by smoking		0.8307
Yes	1.34 (1.04, 1.72) 0.0258	
No	1.38 (1.08, 1.77) 0.0113	
Stratified by diabetes		0.0465
Yes	1.02 (0.69, 1.51) 0.9112	
No	1.63 (1.28, 2.08) < 0.0001	
Model 1 was adjusted for no c	ovariates;	

Model 2 was adjusted for age, gender, and race;

Model 3 was adjusted for all covariates except effect modifier OR, odds ratio; 95% CI, 95% confidence interval and receptor substrate proteins. Additionally, it has been shown that the expression of PTP1B is increased in response to the pro-inflammatory cytokine TNF- α [32]. NF- κ B activation via TLR4/MD-2 causes the production of NLRP3 and IL-1 β and IL-18 precursors. When NLRP3 recognizes different DAMPs, it oligomerizes, activating caspase-1 and causing mature IL-1 β and IL-18 to be produced. By serine phosphorylating IRS1/2, secreted IL-1 suppresses insulin receptor signaling and activates MAPKs via the IL-1 receptor (IL-1R) [33, 34]. In addition, obesity causes IR and macrophage infiltration in adipose tissue, the liver, and skeletal muscle [35]. TyG index has been considered a credible indication of IR, and as inflammation has been linked to both IR and OA, which may be positively correlated.

It needs to be clarified what causes the TyG index to be correlated with OA. Rosa et al. [36] have reported that chondrocytes express functional insulin receptors in human adults. In individuals with OA, chondrocytes have a diminished ability to enhance glucose transport in response to normal physiological levels of insulin. This impairment in glucose transport may harm energy production and the plastic functions of chondrocytes, including the synthesis of glucosaminoglycans. Ultimately, this can lead to chondrocyte damage and the progression of OA. Furthermore, studies have demonstrated that visceral fat, which serves as a substantial source of pro-inflammatory cytokines, can contribute to low-grade chronic metabolic inflammation. This inflammation can potentially lead to joint structural damage and is often associated with IR and T2DM [37]. Moreover, IR is crucial in controlling metabolic syndrome, which raises the risk of OA by maintaining joint inflammation [38]. The impairment of insulin's ability to suppress the production of inflammatory and catabolic mediators responsible for OA would be diminished with the onset of IR in individuals with obesity. Insulin has a pivotal role as a significant modulator of synovial inflammation and catabolism. According to a publication, obese OA patients with T2DM have synovium that develops IR [16]. A greater TyG index is linked to a greater risk of OA, which may be explained by the TyG index's positive correlation with the IR level.

Previous epidemiological research showed that OA risk factors included obesity, smoking, hypertension, and diabetes. Jiang et al. [39] discovered that females were substantially more likely than males to have KOA, with a 5-unit rise in BMI being linked to a 35% greater risk of the condition (p⁶0.05). The pathophysiology of OA has previously been linked to vascular dysfunction [40]. Ching et al. [41] revealed that hypertension's biophysical and biochemical effects on the synovium, subchondral bone, and chondrocytes disrupt joint homeostasis. They may be a factor in the development of OA. Smokers are more likely to develop spinal OA and have more intense and long-lasting pain than non-smokers, according to research by Felson et al. [42]. Thomas Rehling et al. [43] found that OA prevalence was strongly correlated with diabetes [1.3 (1.2–1.4), p[<]0.001]. Our findings of the subgroup analysis show that, in line with previous research, the positive correlation was constant in subgroups stratified by gender, age, BMI, smoking, and diabetes. Furthermore, we found no dependency on BMI, smoking status, or diabetes for this connection (all p for interaction >0.05), indicating that this positive correlation may be suitable for many demographic contexts. However, there existed a higher positive association between TyG index and OA in the individuals without diabetes (p for interaction <0.05).

Current research has several advantages. The NHANES data were used in our investigation, and the appropriate NHANES sample weights were considered while performing the analyses. In addition, we used covariate modifications to lessen the impact of confounding variables, improving the dependability of our results and allowing them to be applied to a larger population. However, it is critical to recognize the constraints built into our research. Personal interviews were used to diagnose OA first, opening the door to the potential of recall bias. Lack of information on pertinent laboratory tests, such as anti-Cyclic Citrullinated Peptide antibodies and Rheumatoid Factor, for the diagnosis and differential diagnosis of OA is another limitation. Moreover, because of NAHNES database restrictions, individuals with OA did not have their occupation or comorbidities included as variables. Furthermore, it should be emphasized that the study design of the NHANES data did not specifically contain information about the differentiation between T1MD and T2MD diabetes. As a result, a more thorough investigation of this connection among subgroups stratified by T1MD and T2MD was not feasible. Furthermore, we chose to use only one imputation for managing the missing data, possibly affecting the accuracy of our findings, given that the missing values of the variables were randomly ignored and the sample size was large enough to draw a firm conclusion. The cross-sectional research design might be blamed for failing to prove a causal connection between TyG and OA.

Conclusion

This research indicates that elevated TyG index values are associated with a higher likelihood of OA prevalence. Hence, we postulate that TyG may serve as a valuable predictor for OA, contributing to the early identification and prevention of OA. However, further extensive prospective studies are necessary to clarify the precise cause of this relationship.

Abbreviations

ALT	Alanine transaminase
AST	Aspartate aminotransferase
BMI	Body mass index
BUN	Blood urea nitrogen
CDC	Centres for Disease Control
CI	Confidence interval
CRP	C-Reactive Protein
GAM	Generalized additive model
HDL cholesterol	High-Density Lipoprotein Cholesterol
HOMA-IR	Homeostatic model assessment of insulin resistance
IR	Insulin resistance
KOA	Knee osteoarthritis
LDL-cholesterol	Low-Density Lipoprotein Cholesterol
NCHS	National Centre for Health Statistics
NHANES	National Health and Nutrition Examination Survey
OA	Osteoarthritis
OR	Odds ratio
PIR	Poverty-to-income ratio
PTP1B	Protein tyrosine phosphatase 1B
SIRI	Systemic inflammatory response index
T1DM	Type 1 diabetes mellitus
T2DM	Type 2 diabetes mellitus
TyG	Triglyceride Glucose
UA	Uric acid

Acknowledgements

Not applicable.

Author contributions

JH and YD designed the research. JH, JL, ZL, and JM collected and analyzed the data. JH, RR, and ZL drafted the manuscript. BF and JH revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

The funding support from the National Natural Science Foundation of China (Grant no. 82274637) for this work is gratefully acknowledged (CW).

Data availability

Publicly available datasets were analyzed in this study. Those data can be found here: www.cdc.gov/nchs/nhanes/.

Declarations

Ethics approval and consent to participate

The NCHS Ethics Review Board examined and approved this study. In order to take part in this study, the patients/participants gave their written informed permission.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 23 September 2023 / Accepted: 4 March 2024 Published online: 11 March 2024

References

- Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377(9783):2115–26.
- 2. Felson DT, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133(8):635–46.
- 3. Glyn-Jones S, et al. Osteoarthr Lancet. 2015;386(9991):376-87.
- Greene MA, Loeser RF. Aging-related inflammation in osteoarthritis. Osteoarthritis Cartilage. 2015;23(11):1966–71.

- Yahaya I, et al. Prevalence of osteoarthritis in lower middle- and lowincome countries: a systematic review and meta-analysis. Rheumatol Int. 2021;41(7):1221–31.
- Global regional, national burden of osteoarthritis. 1990–2020 and projections to 2050: a systematic analysis for the global burden of Disease Study 2021. Lancet Rheumatol. 2023;5(9):e508–22.
- Chowdhury T, et al. The Association between Diabetes Mellitus and Osteoarthritis: does diabetes Mellitus play a role in the Severity of Pain in Osteoarthritis? Cureus. 2022;14(1):e21449.
- Selvi NMK, et al. Association of triglyceride-glucose index (TyG index) with HbA1c and Insulin Resistance in type 2. Diabetes Mellitus Maedica (Bucur). 2021;16(3):375–81.
- Lee SB, et al. Association between triglyceride glucose index and arterial stiffness in Korean adults. Cardiovasc Diabetol. 2018;17(1):41.
- Qin Z, et al. Higher triglyceride-glucose index is Associated with increased likelihood of kidney stones. Front Endocrinol (Lausanne). 2021;12:774567.
- 11. Shi YY, et al. The association between triglyceride glucose index and depression: data from NHANES 2005–2018. BMC Psychiatry. 2021;21(1):267.
- Thai PV, et al. Triglyceride glucose index for the detection of asymptomatic coronary artery stenosis in patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19(1):137.
- 13. Yilmaz M, et al. Triglyceride-glucose index (TyG) is associated with erectile dysfunction: a cross-sectional study. Andrology. 2021;9(1):238–44.
- 14. Duclos M. Osteoarthritis, obesity and type 2 diabetes: the weight of waist circumference. Ann Phys Rehabil Med. 2016;59(3):157–60.
- Eymard F, et al. Diabetes is a risk factor for knee osteoarthritis progression. Osteoarthritis Cartilage. 2015;23(6):851–9.
- 16. Hamada D, et al. Suppressive effects of insulin on Tumor Necrosis factordependent early osteoarthritic changes Associated with obesity and type 2 diabetes Mellitus. Arthritis Rheumatol. 2016;68(6):1392–402.
- Zaharia OP, et al. Reduced muscle strength is Associated with insulin resistance in type 2 diabetes patients with osteoarthritis. J Clin Endocrinol Metab. 2021;106(4):1062–73.
- Bradley D. The intriguing intersection of type 2 diabetes, obesityrelated insulin resistance, and Osteoarthritis. J Clin Endocrinol Metab. 2021;106(5):e2370–2.
- Liu XC, et al. The triglyceride-glucose index, an insulin resistance marker, was non-linear Associated with all-cause and Cardiovascular Mortality in the General Population. Front Cardiovasc Med. 2020;7:628109.
- Chen S, et al. Association between sensitivity to thyroid hormone indices and the risk of osteoarthritis: an NHANES study. Eur J Med Res. 2022;27(1):114.
- 21. Xiao Q, et al. L-shaped association of serum 25-hydroxyvitamin D concentrations with cardiovascular and all-cause mortality in individuals with osteoarthritis: results from the NHANES database prospective cohort study. BMC Med. 2022;20(1):308.
- 22. Chen L, et al. Biological aging mediates the associations between urinary metals and osteoarthritis among U.S. adults. BMC Med. 2022;20(1):207.
- Li W, et al. Insulin resistance and inflammation mediate the association of abdominal obesity with colorectal cancer risk. Front Endocrinol (Lausanne). 2022;13:983160.
- 24. Yan Y, et al. The association between triglyceride glucose index and arthritis: a population-based study. Lipids Health Dis. 2023;22(1):132.
- Qi Q, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158–67.
- 26. Zhou Q, et al. Systemic inflammation response index as an emerging biomarker in osteoarthritis patients: a bibliometric and large sample retrospective investigation. Clin Exp Rheumatol; 2023.
- Li Z et al. P2X7 Receptor Induces Pyroptotic Inflammation and Cartilage Degradation in Osteoarthritis via NF-kB/NLRP3 Crosstalk. Oxid Med Cell Longev, 2021;2021:8868361.
- Philpott HT, O'Brien M, McDougall JJ. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain. 2017;158(12):2442–51.
- 29. Robinson WH, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12(10):580–92.
- Jin J, et al. Limonin inhibits IL-1β-Induced inflammation and catabolism in chondrocytes and ameliorates osteoarthritis by activating Nrf2. Oxid Med Cell Longev. 2021;2021:7292512.
- Qing Z, et al. Vitamin C deficiency aggravates tumor necrosis factor α-induced insulin resistance. Eur J Pharmacol. 2018;829:1–11.

- Nieto-Vazquez I, et al. Insulin resistance associated to obesity: the link TNFalpha. Arch Physiol Biochem. 2008;114(3):183–94.
- Emanuelli B, et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem. 2001;276(51):47944–9.
- Watanabe Y, Nagai Y, Takatsu K. Activation and regulation of the pattern recognition receptors in obesity-induced adipose tissue inflammation and insulin resistance. Nutrients. 2013;5(9):3757–78.
- Li H et al. Macrophages, Chronic Inflammation, and Insulin Resistance. Cells, 2022. 11(19).
- Rosa SC, et al. Expression and function of the insulin receptor in normal and osteoarthritic human chondrocytes: modulation of anabolic gene expression, glucose transport and GLUT-1 content by insulin. Osteoarthritis Cartilage. 2011;19(6):719–27.
- Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415–45.
- Griffin TM, Huffman KM. Editorial: insulin resistance: releasing the brakes on synovial inflammation and osteoarthritis? Arthritis Rheumatol, 2016;68(6):1330–3.

- Jiang L, et al. Body mass index and susceptibility to knee osteoarthritis: a systematic review and meta-analysis. Joint Bone Spine. 2012;79(3):291–7.
- Findlay DM. Vascular pathology and osteoarthritis. Rheumatology (Oxford). 2007;46(12):1763–8.
- Ching K, et al. Hypertension meets osteoarthritis revisiting the vascular aetiology hypothesis. Nat Rev Rheumatol. 2021;17(9):533–49.
- 42. Felson DT, Zhang Y. Smoking and osteoarthritis: a review of the evidence and its implications. Osteoarthritis Cartilage. 2015;23(3):331–3.
- Rehling T, et al. Diabetes is Associated with Musculoskeletal Pain, Osteoarthritis, osteoporosis, and rheumatoid arthritis. J Diabetes Res. 2019;2019:p6324348.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.